Autologous Cell Therapy Platform
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
8
NCT06366490
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 30, 2026
Completion: Dec 30, 2026
Loading map...